Commercial Credit Report for Bioventix PLC

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Bioventix PLC is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Bioventix PLC
7 Roman's Business Park, East Street
Phone: +44 1252728001p:+44 1252728001	FARNHAM, GU9 7SX United Kingdom	Ticker: BVXPBVXP

Business Summary

Bioventix plc is a United Kingdom-based biotechnology company. The Company specializes in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. It has created a sheep hybridoma technology to produce stable and productive cell lines that secrete sheep monoclonal antibodies (SMAs) of very high affinity. Its recombinant FAbs are modified to enable simple conjugation to enzymes (HRP, AP) or biotinylation or association as dimeric FAb2. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function, and drug abuse. It provides ELISA Kits to monitor human exposure to industrial pollutants. It supplies antibody products and services to clinical diagnostics companies.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2023	6/30/2023	Yes	-	-	-	-

Industries

SIC Code	Description
8731	Commercial physical and biological research

Officers and Directors

Title	Name	Age	Title Date	Start Date
Non-Executive Independent Chairman of the Board	Ian J.Nicholson	63
Chief Executive Officer, Director	PeterHarrison
Chief Financial Officer, Director	Bruce E.Hiscock	63	7/1/2020	7/1/2020
Non-Executive Independent Director	NickMccooke		2/13/2014	2/13/2014
Non-Executive Independent Director	JoannePisani		5/30/2023	5/30/2023

General Information

Number of Employees:	16	(As of 6/30/2023)
Outstanding Shares:	5,219,656	(As of 12/31/2023)
Stock Exchange:	LON
Fax Number:	+44 1252728002

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN